Pharma News

Respiratory viruses, typically causing mild illness, can have more serious consequences, as shown during the Covid-19 pandemic, including severe cases requiring hospitalization and the chronic sequelae of long Covid.

The likelihood of developing high blood pressure increases with higher levels of tellurium, a contaminant transferred from mining and manufacturing activities to foods. Improved monitoring of tellurium levels in specific foods could help decrease high blood pressure in the general population. The results of a study examining the relationship between tellurium exposure and hypertension were published in the journal Environment International.

In a hopeful sign for safe, effective antibiotics for humans, researchers at The University of Texas at Austin have leveraged aritificial intelligence to develop a new drug that already is showing promise in animal trials. Publishing their results today in Nature Biomedical Engineering, the scientists describe using a large language model an AI tool like the one that powers ChatGPT to engineer a version of a bacteria-killing drug that was previously toxic in humans, so that it would be safe to use.

Since early June 2024, Acute Encephalitis Syndrome cases have been reported from Gujarat in children under 15 years of age. As on 31st July 2024, 148 AES cases 140 from 24 districts of Gujarat, 4 from Madhya Pradesh, 3 from Rajasthan & 1 from Maharashtra have been reported, out of which 59 cases have died. Chandipura virus has been confirmed in 51 cases.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific APAC, Latin America LATAM, Europe, and Middle East regions.

Zydus Life Sciences is engaged in a legal battle with Roche over its biosimilar, Sigrima, which is based on Roches Perjeta Pertuzumab, targeting the human epidermal growth factor receptor 2-positive breast cancer market in India.

As per the provisions of Drugs Order, 2013 , formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule –I are defined under Para of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013.

Startup India Initiative, launched on January 16, 2016, which aims to foster innovation and encourage investments across various industries, including the pharmaceutical sector. The initiative includes three flagship schemes viz., Fund of Funds for Startups; Startup India Seed Fund Scheme; and Credit Guarantee Scheme for Startups